Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

Patients with the urticarial form of BP may never develop typical BP bullae, but continue to exhibit skin lesions typical of urticarial dermatitis (Kossard, Hamann, & Wilkinson, 2006). Histologic ...

Urticarial vasculitis (UV) presents atypical urticarial lesions and leukocytoclastic vasculitis, sometimes involving other organs. Biologics have shown potential in refractory cases unresponsive to ...

Bullous Pemphigoid Market Outlook 2025-2035: The 7 major Bullous Pemphigoid market reached a value of USD 287.1 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,618.1 ...

Treatment should make BP more tolerable to each individual patient through the reduction of blister formation, urticarial lesions, and pruritus. Prior to the use of oral corticosteroids ...